



Supplementary Information


Supplementary Figures




Supplementary Fig. 1 Characterization of nanoformulation candidates. Formulation reproducibility of screen 'hits' (error bars denote ± 1 SD; three repeats) with concordance between full-scale and half-scale EFTD; ^3H -labelled atovaquone inclusion used on half-scale SDN synthesis.




Supplementary Fig. 2 Comparison of rapid equilibrium dialysis release rate measurements of ^{ATQ}SDN₄ at 20 (^{ATQ}SDN₄₋₂₀), 40 (^{ATQ}SDN₄₋₄₀), 60 (^{ATQ}SDN₄₋₆₀) and 80 (^{ATQ}SDN₄₋₈₀) wt% drug loading. For release rate studies, samples were prepared incorporating ³H-atovaquone at 0.2 μCi mg⁻¹ specific activity. ^{ATQ}SDN₄ was selected on the basis that it exhibited the highest release rate in the initial screen.




Supplementary Fig. 3 Comparison of rapid equilibrium dialysis release rate measurements of ^{ATQ}SDN₆ at 20 (^{ATQ}SDN₆₋₂₀), 40 (^{ATQ}SDN₆₋₄₀), 60 (^{ATQ}SDN₆₋₆₀) and 80 (^{ATQ}SDN₆₋₈₀) wt% drug loading. For release rate studies, samples were prepared incorporating ³H-atovaquone at 0.2 μCi mg⁻¹ specific activity. ^{ATQ}SDN₆ was selected on the basis that it exhibited the lowest release rate in the initial screen.



Supplementary Fig. 4 Comparison of rapid equilibrium dialysis release rate measurements of ^{ATQ}SDN₈ at 20 (^{ATQ}SDN₈₋₂₀), 40 (^{ATQ}SDN₈₋₄₀), 60 (^{ATQ}SDN₈₋₆₀) and 80 (^{ATQ}SDN₈₋₈₀) wt% drug loading. For release rate studies, samples were prepared incorporating ³H-atovaquone at 0.2 μ Ci mg⁻¹ specific activity. ^{ATQ}SDN₈ was selected on the basis that it exhibited an intermediate release rate in the initial screen.



Supplementary Fig. 5 Rapid equilibrium dialysis release rates of ^{ATQ}SDN nanoformulations with systematically varying atovaquone loading relative to excipients at 6 hours. ^{ATQ}SDN₄ (A), ^{ATQ}SDN₆ (B) and ^{ATQ}SDN₈ (C) were selected on the basis that they exhibited the highest, lowest and intermediate release rate during screening, respectively.



Supplementary Fig. 6 Biological testing of ^{ATQ}SDN₈. **a**, Plasma was collected at indicated intervals for assay of atovaquone concentrations in mice dosed intramuscularly with 200 mg kg⁻¹ ^{ATQ}SDN₈. Log-transformed concentrations yield a plasma half-life of 163 h (using 4 - 42 d values, inclusive; R², 0.889); data obtained in 4 independent experiments. **b**, Plasma atovaquone concentrations >200 ng mL⁻¹ at the time of challenge correlate closely with efficacy. Each dot represents a cohort of 3-5 mice, 7 to 42 d after a single intramuscular dose of 50, 100 or 200 mg kg⁻¹ ^{ATQ}SDN₈. Data from four independent experiments.

Supplementary Tables

Supplementary Table 1: Nanoformulation ‘hits’ from synthesis screen. All contain 80 wt% atovaquone.

Formulation	Polymer (13% by weight)	Surfactant (7% by weight)	D_z^a (nm)	PdI^b	Zeta Potential (mV)
^{ATQ} SDN ₁	Kollicoat	TPGS	477	0.281	8.2
^{ATQ} SDN ₂	PVP K30	TPGS	346	0.261	-19.5
^{ATQ} SDN ₃	Kollicoat	Tween 20	440	0.322	-16.3
^{ATQ} SDN ₄	PVP K30	Tween 20	388	0.284	-16.4
^{ATQ} SDN ₅	PVA	Tween 80	526	0.369	-20.4
^{ATQ} SDN ₆	Kollicoat	Tween 80	454	0.309	-12.8
^{ATQ} SDN ₇	PVP K30	Tween 80	298	0.296	-16.4
^{ATQ} SDN ₈	PVA	NDC	445	0.345	-12.2
^{ATQ} SDN ₉	PVA	Solutol	517	0.352	-15.5
^{ATQ} SDN ₁₀	Kollicoat	Solutol	440	0.332	-17.0
^{ATQ} SDN ₁₁	PVP K30	Solutol	384	0.337	-17.2

^a D_z = Z-average diameter; ^b PdI = Polydispersity index

Supplementary Table 2: Physical characterisation of ^{ATQ}SDN nanoformulations with systematically varying drug loading relative to excipients. For release rate studies, samples were prepared incorporating ³H-atovaquone at 0.2 $\mu\text{Ci mg}^{-1}$ specific activity.

Sample	ATQ wt%	Name	wt%	Name	wt%	D_z (nm) ^a	PdI ^b
^{ATQ} SDN ₄₋₂₀	20	PVP K30	52	Tween 20	28	505	0.151
^{ATQ} SDN ₄₋₄₀	40	PVP K30	39	Tween 20	21	407	0.222
^{ATQ} SDN ₄₋₆₀	60	PVP K30	26	Tween 20	14	439	0.322
^{ATQ} SDN ₆₋₂₀	20	Kollicoat	52	Tween 80	28	669	0.226
^{ATQ} SDN ₆₋₄₀	40	Kollicoat	39	Tween 80	21	468	0.236
^{ATQ} SDN ₆₋₆₀	60	Kollicoat	26	Tween 80	14	510	0.302
^{ATQ} SDN ₈₋₂₀	20	PVA	52	NDC	28	891	0.199
^{ATQ} SDN ₈₋₄₀	40	PVA	39	NDC	21	524	0.322
^{ATQ} SDN ₈₋₆₀	60	PVA	26	NDC	14	438	0.256

^a D_z = Z-average diameter; ^b PdI = Polydispersity index